US pharma giant Pfizer (NYSE: PFE) has announced a 1% decline in sales and a 3% increase in earnings per share in first -quarter 2017, compared with the same period last year.
Total revenue stood at $12.8 billion, short of analysts’ expectations. The earnings per share figure, following generally accepted accounting principles (GAAP), was $0.69.
For the second quarter running, the company pointed the finger at a shorter selling period to explain the decline, noting there was one less business day in the USA this quarter and two fewer globally.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze